"I was fighting to survive": Patients still struggle with preauthorization despite promise of reform

Last summer, the Trump administration announced a voluntary pledge by health insurers to reform prior authorization, but patient advocates and medical providers remain skeptical.

argenx SE: Excellent Company, Premium Valuation

SE has achieved rapid commercial success with VYVGART, driving $4.2 billion in 2025 sales and operational profitability. Learn more about ARGX stock here.
TMCnet

argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data ...
Le Lézard

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Stan…

Johnson & Johnson , a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...
BioSpace

argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...
MedPage Today

FcRn Inhibitors Play an Evolving Role in Myasthenia Gravis Treatment

Three drugs that inhibit the immunoglobulin G (IgG) neonatal fragment crystallizable receptor (FcRn) were approved to treat generalized myasthenia gravis (MG) in recent years: efgartigimod (Vyvgart), ...